{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:55:58Z","timestamp":1786449358177,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This systematic review and meta-regression analysis assessed the impact of human papillomavirus 16\/18 (HPV16\/18)-AS04 vaccine (Cervarix\u00ae) on advanced cervical lesions, including grade 3 cervical intraepithelial neoplasia or worse (CIN3, CIN3+), or cervical cancer, highlighting age-at-vaccination\u2013dependent vaccine efficacy and effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Studies reporting HPV16\/18-AS04 vaccine efficacy or effectiveness were included with an intervention group receiving HPV16\/18-AS04 vaccine and comparator group receiving placebo, another vaccine or being unvaccinated. Of 53 articles identified, nine were selected. Meta-analysis and meta-regression models with random effects and data-driven model selection determined vaccine effects (VEs) and impactful covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HPV16\/18-AS04 vaccine effectively prevented advanced cervical premalignant lesions and cancer in adolescent girls and women vaccinated at 12\u201325\u00a0years. Combined randomized controlled trials and observational studies VEs on CIN3+ ranged between 76.78% (95% CI 28.15\u201392.49) for HPV16\/18 and 56.19% (95% CI 24.76\u201374.49) irrespective of HPV type. Vaccine effectiveness was greatest in those vaccinated at the youngest ages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HPV16\/18-AS04 vaccine provides long-term protection against cervical premalignant lesions and cervical cancer in both controlled and real-world settings, particularly when administered at younger ages. The evidence urges policymakers and the community to ensure HPV vaccination begins at the youngest recommended ages.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/pubmed\/fdag002","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:19:04Z","timestamp":1769750344000},"page":"216-227","source":"Crossref","is-referenced-by-count":2,"title":["Maximizing impact: the power of early HPV vaccination for long-term protection\u2015lessons from a systematic review and meta-regression analysis"],"prefix":"10.1093","volume":"48","author":[{"given":"Adoraci\u00f3n","family":"Navarro-Torn\u00e9","sequence":"first","affiliation":[{"name":"Viral Non-Respiratory, Vaccines and Infectious Disease Epidemiology, GSK , Tres Cantos 28760 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8640-1742","authenticated-orcid":false,"given":"Emmanuel","family":"Aris","sequence":"additional","affiliation":[{"name":"Real-World Biostatistics, GSK , Wavre 1300 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4805-5118","authenticated-orcid":false,"given":"Andrea","family":"Callegaro","sequence":"additional","affiliation":[{"name":"Statistics, GSK, Rixensart 1330 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Benninghoff","sequence":"additional","affiliation":[{"name":"A&N Immugen, Egloffstein 91349 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0158-1797","authenticated-orcid":false,"given":"Huifeng","family":"Yun","sequence":"additional","affiliation":[{"name":"Viral Non-Respiratory, Vaccines and Infectious Disease Epidemiology, GSK , Rockville, MD 20850 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Vetter","sequence":"additional","affiliation":[{"name":"Global Medical Lead, GSK , Wavre 1300 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2026030608370324800_ref1","doi-asserted-by":"publisher","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Forman","year":"2012","journal-title":"Vaccine"},{"key":"2026030608370324800_ref2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bpobgyn.2017.08.015","article-title":"The natural history of human papillomavirus infection","volume":"47","author":"Sanjose","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2026030608370324800_ref3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/v13020321","article-title":"Persistent human papillomavirus infection","volume":"13","author":"Della Fera","year":"2021","journal-title":"Viruses"},{"key":"2026030608370324800_ref4","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"key":"2026030608370324800_ref5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"2026030608370324800_ref6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","article-title":"Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature","volume":"404","author":"Wei","year":"2024","journal-title":"Lancet"},{"key":"2026030608370324800_ref7","article-title":"Human papillomavirus and related diseases in the world","volume":"10","author":"Bruni","year":"2023","journal-title":"Summary Report"},{"key":"2026030608370324800_ref8","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jadohealth.2010.01.016","article-title":"Beyond cervical cancer: burden of other HPV-related cancers among men and women","volume":"46","author":"Chaturvedi","year":"2010","journal-title":"J Adolesc Health"},{"key":"2026030608370324800_ref9","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the advisory committee on immunization practices","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026030608370324800_ref10","doi-asserted-by":"crossref","first-page":"1067299","DOI":"10.3389\/fpubh.2023.1067299","article-title":"Gender neutral HPV vaccination programs: reconsidering policies to expand cancer prevention globally","volume":"11","author":"Dykens","year":"2023","journal-title":"Front Public Health"},{"key":"2026030608370324800_ref11","doi-asserted-by":"crossref","first-page":"1393897","DOI":"10.3389\/fped.2024.1393897","article-title":"Assessing the long-term implications of age 9 initiation of HPV vaccination on series completion by age 13\u201315 in the US: projections from an age-structured vaccination model","volume":"12","author":"Saxena","year":"2024","journal-title":"Front Pediatr"},{"key":"2026030608370324800_ref12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.15585\/mmwr.mm7333a1","article-title":"National vaccination coverage among adolescents aged 13-17 years - national immunization survey-teen, United States, 2023","volume":"73","author":"Pingali","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026030608370324800_ref13","article-title":"Cervical cancer elimination initiative","author":"WHO","year":"2024"},{"key":"2026030608370324800_ref14","article-title":"Cervarix SmPC","author":"EMA","year":"2012"},{"key":"2026030608370324800_ref15","first-page":"360","article-title":"Understanding interobserver agreement: the kappa statistic","volume":"37","author":"Viera","year":"2005","journal-title":"Fam Med"},{"key":"2026030608370324800_ref16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026030608370324800_ref17","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5: Chapter 13: Assessing Risk of Bias Due to Missing Evidence in a Meta-Analysis [Last Updated August 2024]","author":"Page","year":"2024"},{"key":"2026030608370324800_ref18","doi-asserted-by":"publisher","first-page":"l1161","DOI":"10.1136\/bmj.l1161","article-title":"Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study","volume":"365","author":"Palmer","year":"2019","journal-title":"BMJ"},{"key":"2026030608370324800_ref19","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5: Chapter 8: Assessing Risk of Bias in a Randomized Trial","author":"Higgins","year":"2024"},{"key":"2026030608370324800_ref20","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5: Chapter 25: Assessing Risk of Bias in a Non-randomized Study","author":"Sterne","year":"2024"},{"key":"2026030608370324800_ref21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026030608370324800_ref22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026030608370324800_ref23","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.4161\/hv.28712","article-title":"Efficacy of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women","volume":"10","author":"Konno","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"2026030608370324800_ref24","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/S1470-2045(20)30524-6","article-title":"Efficacy of the bivalent HPV vaccine against HPV 16\/18-associated precancer: long-term follow-up results from the Costa Rica vaccine trial","volume":"21","author":"Porras","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026030608370324800_ref25","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(22)00291-1","article-title":"Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV vaccine trial","volume":"23","author":"Shing","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026030608370324800_ref26","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"key":"2026030608370324800_ref27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41416-022-01791-w","article-title":"The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot","volume":"127","author":"Rebolj","year":"2022","journal-title":"Br J Cancer"},{"key":"2026030608370324800_ref28","doi-asserted-by":"publisher","first-page":"e015867","DOI":"10.1136\/bmjopen-2017-015867","article-title":"Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials","volume":"7","author":"Lehtinen","year":"2017","journal-title":"BMJ Open"},{"key":"2026030608370324800_ref29","first-page":"75","article-title":"Empirical bayes meta-analysis. J Educ","volume":"10","author":"Raudenbush","year":"1985","journal-title":"Stat"},{"key":"2026030608370324800_ref30","doi-asserted-by":"publisher","first-page":"e29420","DOI":"10.1002\/jmv.29420","article-title":"Risk factors for human papillomavirus infection and disease: a targeted literature summary","volume":"96","author":"Del Pino","year":"2024","journal-title":"J Med Virol"},{"key":"2026030608370324800_ref31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"2026030608370324800_ref32","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S1470-2045(11)70213-3","article-title":"Efficacy of a bivalent HPV 16\/18 vaccine against anal HPV 16\/18 infection among young women: a nested analysis within the Costa Rica vaccine trial","volume":"12","author":"Kreimer","year":"2011","journal-title":"Lancet Oncol"},{"key":"2026030608370324800_ref33","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/S1473-3099(20)30873-2","article-title":"Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials","volume":"21","author":"Mariz","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026030608370324800_ref34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-023-00628-8","article-title":"Differences in HPV-specific antibody fc-effector functions following Gardasil(R) and Cervarix(R) vaccination","volume":"8","author":"Roy","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2026030608370324800_ref35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.vaccine.2022.11.057","article-title":"High vaccine effectiveness persists for ten years after HPV16\/18 vaccination among young Dutch women","volume":"41","author":"Hoes","year":"2023","journal-title":"Vaccine"},{"key":"2026030608370324800_ref36","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/jnci\/djad263","article-title":"Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation","volume":"116","author":"Palmer","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"2026030608370324800_ref37","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1002\/cam4.1155","article-title":"Ten-year immune persistence and safety of the HPV-16\/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age","volume":"6","author":"Schwarz","year":"2017","journal-title":"Cancer Med"},{"key":"2026030608370324800_ref38","doi-asserted-by":"crossref","first-page":"100293","DOI":"10.1016\/j.eclinm.2020.100293","article-title":"A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs","volume":"22","author":"Demarco","year":"2020","journal-title":"EClinicalMedicine"}],"container-title":["Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpubhealth\/article-pdf\/48\/1\/216\/66636164\/fdag002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpubhealth\/article-pdf\/48\/1\/216\/66636164\/fdag002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:37:15Z","timestamp":1772804235000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpubhealth\/article\/48\/1\/216\/8444869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,30]]},"published-print":{"date-parts":[[2026,3,6]]}},"URL":"https:\/\/doi.org\/10.1093\/pubmed\/fdag002","relation":{},"ISSN":["1741-3842","1741-3850"],"issn-type":[{"value":"1741-3842","type":"print"},{"value":"1741-3850","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,1,30]]}}}